Amniotic membrane-based antimicrobial agent

Background

During the years 2000 and 2015, the use of antibiotics worldwide increased for 65%. Epidemiological studies showed the correlation between the increasing use of antibiotics and the emergence and spreading of bacteria, resistant to antibiotics. The studies show there is a great need for discovery and development of novel antimicrobials.

Description of the Invention

The developed mammalian amniotic membrane homogenate can be used as an antimicrobial agent. The preparation of which runs through a well-determined procedure so that its antibacterial characteristics remain intact.

Main Advantages

Antimicrobial activity of amniotic membrane has been proven against several bacteria, namely Escherichia coli, Staphylococcus aureus,  Enterobacter sp., Klebsiella pneumoniae, Staphylococcus saprophyticus and others. The preparation procedure is simple and cost-effective and the homogenate presents a high efficacy rate.

Developed by
University of Ljubljana, Medical Faculty
Reference
UL20180381012

Get in touch with us

ipr@uni-lj.si

Solutions to your challenges

More information

Would you like to be kept up-to-date on our new technologies?

Subscribe to TechAlert